Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

AURORA, Ontario, Oct. 29 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced financial results for the year ended July 31, 2009.

During the 2009 fiscal year, the Company continued to make progress with its development initiatives for its lead drug candidates, L-DOS47 and Topical Interferon Alpha-2b. The following are selected highlights during the 2009 fiscal year and subsequent to year-end.

FISCAL 2009 HIGHLIGHTS

DOS47/L-DOS47

  • A pre-IND meeting with the U.S. Food and Drug Administration ("FDA") was held for L-DOS47 in which the FDA generally agreed with Helix's proposed remaining non-clinical pharmacology and toxicology studies as well as its remaining GMP manufacturing program initiatives prior to IND filing.
  • Helix announced plans to conduct a Phase I/II clinical study of non-small cell lung cancer ("NSCLC") patients in Poland. Helix has been finalizing these plans with key opinion leader clinicians and contract research organizations in Poland. The study is expected to run concurrently with the U.S. Phase I trial in refractory solid tumor patients. The timing of both studies will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.

Topical Interferon Alpha-2b

  • A pre-IND meeting with the FDA was held in which the FDA confirmed the acceptability of a Phase II/III, randomized, vehicle-controlled clinical trial as the next step in the compound's clinical development plan for patients with cervical dysplasia. The FDA also confirmed Helix's expectation that an additional well-controlled, Phase III confirmatory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose.
  • The Phase II pharmacokinetic
    '/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Encision Inc. (OTCQB:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... ended June 30, 2014. The Company posted ... net loss of $202 thousand, or $(0.02) per share. ... for a net loss of $311 thousand, or $(0.04) ...
(Date:7/29/2014)... , Next phase of ... has commenced , TPM®/Oxycodone Phase 2a trial ... 2014 , TPM®/Oxymorphone Phase 2 trial to ... Australian drug delivery company, Phosphagenics Limited (ASX: ... programs after its recent announcement of a $19.2 million capital raising. ...
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3
... Hospira, Inc. (NYSE: HSP ... announced positive results from a Phase I U.S. clinical ... renal (kidney) dysfunction who have anemia. Hospira,s trial met ... and distribution in the body, for Hospira,s EPO and ...
... 6, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... and Chief Executive Officer, will present at the Rodman ... 2011 at 2:25pm ET at the Waldorf Astoria Hotel ... Pharmaceuticals, Inc. Founded in 2008, Omthera ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to an ... uterine fibroid was recently removed from a 52 year old ... woman, identified only as Latha, reportedly had no idea that ... had been experiencing fatigue and breathlessness for years, but did ... Kumaran Hospital in Chennai only discovered the massive uterine fibroid ...
(Date:7/29/2014)... Francisco, California (PRWEB) July 29, 2014 ... reach USD 9,542.3 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... of these devices by the geriatric population, along with ... some of the major drivers of this market. In ...
(Date:7/29/2014)... iFitDress.com, one of the most famous dress ... 2014 high low wedding dresses . Aside from that, ... at discounted prices, up to 68% off. All the company’s ... before August 05. , The company’s sales representative is ... dresses. In the new collection, there are numerous great gowns ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6Health News:2014 High Low Wedding Dresses Provided By iFitDress.com 2Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3
... release is available in French . , ... on possible links between cell phone use and brain ... collaborated on the Interphone International Study Group. Jack Siemiatycki, ... epidemiologist at the University of Montreal Hospital Research Center, ...
... HACKENSACK, N.J. (May 17, 2010) John Theurer Cancer Center ... is one of two cancer centers in the tri-state ... DVS (Dose Verification System). John Theurer Cancer Center radiation ... the precise amount of radiation being delivered to tumors ...
... could pave way for tests that predict the illness, researchers ... of serious lung disease in middle age may have genetic ... history of such illnesses in their background, a new study ... might enable doctors to screen for genetic predispositions to serious ...
... ... in the May 17 – 21 event , ... (PRWEB) May 17, 2010 -- Pedego® Electric Bicycles has ... throughout Northern California, has added the Pedego Comfort Cruiser line of electric bikes to ...
... ... keep Affiliates informed on how to achieve the highest conversion performance. , ... Encino, CA (PRWEB) May 14, ... technology concerning the affiliate marketing industry. Founded in 2006, T3Leads has since provided unparalleled ...
... ... Patients Reverse Sun Damage and Restore the Health of Their Skin without Painful Surgery ... Los Angeles ... damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. While a ...
Cached Medicine News:Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:John Theurer Cancer Center offers breakthrough radiation measurement technology 2Health News:Lung Disease Can Be Genetic Even Without Family History 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 3Health News:Epione Reveals a ‘Bright' New Solution for Dull, Sun Damaged Skin 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: